Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964544 · ClinicalTrials.gov registry record · Phase 3
Technology-Assisted Cholesterol Trial in Consumers (TACTiC)
A Phase 3 study of High Cholesterol, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,196
- Enrollment target
- 1
- Study location
NCT04964544: Completed Phase 3 study of High Cholesterol, sponsored by AstraZeneca.
NCT04964544 is a Phase 3 study of High Cholesterol that has completed, run by AstraZeneca. The registered enrollment target is 1,196 participants, above the 168-participant average among 4 other High Cholesterol trials with a reported enrollment target (612% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04964544, a Phase 3 study of High Cholesterol, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,196 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this AUS is to evaluate the extent to which participants can safely and effectively self-select, purchase, and use Crestor OTC 5 mg for a 6-month period according to the label.
Primary Outcome
Proportion of participants that had a correct tass outcome at their initial TASS assessment
Conditions Studied
Interventions
- COMBINATION_PRODUCT 5 mg rosuvastatin calcium with a Web App (combination product)
Study Locations (1)
Indiana
- Research Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,196 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 3 |
What the finished NCT04964544 record still lists
NCT04964544 is an interventional study that assigns participants to a tested intervention. Its 1,196 participants enrollment target places it among the larger protocols in the corpus, above the 168-participant average among 4 other High Cholesterol trials with a reported enrollment target (612% higher).
The record links to 1 condition, with High Cholesterol appearing as the primary indexed condition, and to 1 intervention - of which 5 mg rosuvastatin calcium with a Web App (combination product) is the first listed.
NCT04964544 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04964544 about?
NCT04964544 is a clinical study titled "Technology-Assisted Cholesterol Trial in Consumers (TACTiC)". The purpose of this AUS is to evaluate the extent to which participants can safely and effectively self-select, purchase, and use Crestor OTC 5 mg for a 6-month period according to the label.
What is the current status of trial NCT04964544?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,196 participants. The study started on 2021-07-08. Estimated completion is 2023-03-01.
What conditions does trial NCT04964544 study?
This clinical trial studies the following conditions: High Cholesterol.
What interventions are being tested in trial NCT04964544?
The interventions under investigation include: 5 mg rosuvastatin calcium with a Web App (combination product) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04964544?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04964544 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Cholesterol
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI